José M Porcel1, Horacio Valencia2, Silvia Bielsa2. 1. Pleural Medicine Unit, Department of Internal Medicine, Arnau de Villanova University Hospital, Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDA, Avda Alcalde Rovira Roure 80, 25198, Lleida, Spain. jporcelp@yahoo.es. 2. Pleural Medicine Unit, Department of Internal Medicine, Arnau de Villanova University Hospital, Institute for Biomedical Research Dr Pifarre Foundation, IRBLLEIDA, Avda Alcalde Rovira Roure 80, 25198, Lleida, Spain.
Abstract
PURPOSE: We sought to evaluate the safety profile and effectiveness of manual pleural saline flushing, in addition to urokinase, for managing complicated parapneumonic effusions and empyemas. METHODS: Retrospective comparative review of 23 consecutive patients with complicated parapneumonic effusions or empyemas who received saline flushing plus urokinase through small-bore chest catheters, and 39 who were only treated with fibrinolytics. Both groups had similar baseline characteristics and treatments were mostly protocol-driven. RESULTS: As compared with patients only receiving urokinase, those additionally treated with saline flushing needed less fibrinolytic doses (a single dose being sufficient in 15 vs 44%, p = 0.019), chest tube duration (5 vs 2 days, p < 0.01), and length of hospital stay (8 vs 6 days, p = 0.011). There were no adverse events attributed to saline therapy. CONCLUSIONS: Manual pleural saline flushing via chest tube, in addition to urokinase, is a safe and potentially beneficial therapy in patients with pleural infection.
PURPOSE: We sought to evaluate the safety profile and effectiveness of manual pleural saline flushing, in addition to urokinase, for managing complicated parapneumonic effusions and empyemas. METHODS: Retrospective comparative review of 23 consecutive patients with complicated parapneumonic effusions or empyemas who received salineflushing plus urokinase through small-bore chest catheters, and 39 who were only treated with fibrinolytics. Both groups had similar baseline characteristics and treatments were mostly protocol-driven. RESULTS: As compared with patients only receiving urokinase, those additionally treated with saline flushing needed less fibrinolytic doses (a single dose being sufficient in 15 vs 44%, p = 0.019), chest tube duration (5 vs 2 days, p < 0.01), and length of hospital stay (8 vs 6 days, p = 0.011). There were no adverse events attributed to saline therapy. CONCLUSIONS: Manual pleural saline flushing via chest tube, in addition to urokinase, is a safe and potentially beneficial therapy in patients with pleural infection.
Authors: M Falguera; J Carratalà; S Bielsa; C García-Vidal; A Ruiz-González; I Chica; F Gudiol; J M Porcel Journal: Eur Respir J Date: 2011-05-12 Impact factor: 16.671
Authors: Carmen Alemán; José M Porcel; José Alegre; Eva Ruiz; Silvia Bielsa; Jordi Andreu; Maria Deu; Pilar Suñé; Mireia Martínez-Sogués; Iker López; Esther Pallisa; Joan Antoni Schoenenberger; J Bruno Montoro; Tomás Fernández de Sevilla Journal: Lung Date: 2015-09-30 Impact factor: 2.584
Authors: Clare E Hooper; Anthony J Edey; Anthony Wallis; Amelia O Clive; Anna Morley; Paul White; Andrew R L Medford; John E Harvey; Mike Darby; Natalie Zahan-Evans; Nick A Maskell Journal: Eur Respir J Date: 2015-05-28 Impact factor: 16.671
Authors: Sally M Lansley; Hui Min Cheah; Julius F Varano Della Vergiliana; Aron Chakera; Y C Gary Lee Journal: Am J Respir Cell Mol Biol Date: 2015-07 Impact factor: 6.914
Authors: Najib M Rahman; Nicholas A Maskell; Alex West; Richard Teoh; Anthony Arnold; Carolyn Mackinlay; Daniel Peckham; Chris W H Davies; Nabeel Ali; William Kinnear; Andrew Bentley; Brennan C Kahan; John M Wrightson; Helen E Davies; Clare E Hooper; Y C Gary Lee; Emma L Hedley; Nicky Crosthwaite; Louise Choo; Emma J Helm; Fergus V Gleeson; Andrew J Nunn; Robert J O Davies Journal: N Engl J Med Date: 2011-08-11 Impact factor: 91.245
Authors: Nicholas A Maskell; Christopher W H Davies; Andrew J Nunn; Emma L Hedley; Fergus V Gleeson; Robert Miller; Rhian Gabe; Glyn L Rees; Timothy E A Peto; Mark A Woodhead; Donald J Lane; Janet H Darbyshire; Robert J O Davies Journal: N Engl J Med Date: 2005-03-03 Impact factor: 91.245
Authors: Najib M Rahman; Brennan C Kahan; Robert F Miller; Fergus V Gleeson; Andrew J Nunn; Nicholas A Maskell Journal: Chest Date: 2014-04 Impact factor: 9.410
Authors: Tamsin N Cargill; Maged Hassan; John P Corcoran; Elinor Harriss; Rachelle Asciak; Rachel M Mercer; David J McCracken; Eihab O Bedawi; Najib M Rahman Journal: Eur Respir J Date: 2019-10-01 Impact factor: 16.671
Authors: José M Porcel; Lucia Ferreiro; Laura Rumi; Esther Espino-Paisán; Carmen Civit; Marina Pardina; Juan Antonio Schoenenberger-Arnaiz; Luis Valdés; Silvia Bielsa Journal: Pleura Peritoneum Date: 2020-02-26